Sekar Kathiresan - 17 Jun 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Issuer symbol
VERV
Transactions as of
17 Jun 2021
Net transactions value
+$47,500
Form type
4
Filing time
21 Jun 2021, 18:20:58 UTC
Previous filing
16 Jun 2021
Next filing
27 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Purchase $47,500 +2,500 +0.62% $19.00 406,536 21 Jun 2021 Direct
holding VERV Common Stock 80,997 17 Jun 2021 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 80,997 17 Jun 2021 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +53,998 $0.000000 53,998 17 Jun 2021 Common Stock 53,998 $19.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 17, 2021. 25% of the shares underlying the option will vest on June 17, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until June 17, 2025.